Introduction {#Sec1}
============

Steroid-resistant nephrotic syndrome (SRNS) occurs at an estimated incidence of 1 per 200,000 children. Genetic causes can be identified in nearly 50 % of affected children with this highly heterogeneous disorder (Löwik et al. [@CR10]; Benoit et al. [@CR1]). Genetic forms of SRNS do not respond to intensified immunosuppressive treatment and progress inevitably to end-stage kidney disease, but, on the other hand, have minimal risk of post-transplant recurrence. Hence, genetic testing is of eminent clinical relevance in this complex group of patients (Jungraithmayr et al. [@CR6]; Santín et al. [@CR16]).

In hereditary SRNS, abnormalities in podocyte-specific genes cause structural defects of the glomerular filtration barrier (Hinkes et al. [@CR5]; Löwik et al. [@CR10]). Defective genes involve the structure and function of the slit diaphragm (e.g. *NPHS1*, *NPHS2*), the actin cytoskeleton (e.g. *ACTN4*, *INF2*) or podocyte differentiation (*WT1*) (Löwik et al. [@CR10]; Benoit et al. [@CR1]; Santín et al. [@CR16]).

*NPHS2* encodes podocin, a membrane protein that links the slit diaphragm protein nephrin to the cytoskeleton. *NPHS2* mutations constitute the most common genetic cause of SRNS (Hinkes et al. [@CR5]; Santín et al. [@CR17]; Lipska et al. [@CR8]). The *NPHS2* gene is located on chromosome 1p25-31 and consists of eight exons. To date, approximately 120 different point mutations localised along the entire coding sequence of the gene have been reported.

The aim of the study was to determine the prevalence and spectrum of *NPHS2* gene mutations in a nation-wide cohort of Polish children with SRNS and to compare the spectrum of mutations with those described in other European populations.

Materials and methods {#Sec2}
=====================

Mutational screening {#Sec3}
--------------------

A total of 141 patients with a clinical diagnosis of SRNS from 13 Polish paediatric nephrology centres were enrolled in the study. Detailed analysis of the clinical parameters of the studied group is out of the scope of the current report and will be the subject of a separate study.

DNA was extracted from blood samples using the standard phenol--chloroform procedure. The complete coding sequence of the *NPHS2* gene, including splice junctions, was subject to direct bi-directional sequencing (Applied Biosystems). All novel variants were verified in the dbSNP, the 1000 Genomes catalogue and the NHLBI Exome Sequencing Project. The trans-character of the compound heterozygous cases was confirmed by testing parents. To assess the effect of the detected novel sequence variants on the structure and function of the protein, a number of bioinformatics tools were used, including the UCSC Genome Bioinformatics and UniProtKB web resources, along with the PolyPhen-2 and SIFT online algorithms. The Human Splicing Finder and ESEfinder web interfaces were used to evaluate the potential effect on the splicing process.

Population genotyping {#Sec4}
---------------------

Dried blood specimens from 575 consecutively screened neonates representative for the Kashubian districts of North Poland were used as a population-matched control group. DNA was extracted from 1--3-mm^2^ pieces of dried blood specimens that were incubated in 50 μl of TE buffer at 95 °C for 1 h; after incubation, samples were centrifuged at room temperature at 1,400 × g for 10 min to eliminate physical contamination. The supernatant was used as the DNA template. The *NPHS2* p.R229Q genotype was determined by restriction fragment length polymorphism (RFLP) using Bsu15I (ClaI) enzyme (Thermo Scientific), while the c.1032delT genotype was analysed by real-time polymerase chain reaction (real-time PCR) assay with allele-specific TaqMan probes (LightCycler 480 II, Roche).

Written informed consent was obtained from the relevant guardians of the children and from patients themselves, whenever eligible. The study was approved by the Ethical Committee of the Medical University of Gdansk, Poland.

Results {#Sec5}
=======

Spectrum of *NPHS2* mutations in Polish patients {#Sec6}
------------------------------------------------

Twenty patients comprising 14 % of the studied cohort fulfilled the criteria of podocin-associated SRNS. Fifteen were compound heterozygous cases; 11 of these harboured the c.1032delT mutation and four carried other known mutations. The remaining five cases showed homozygous mutations (Table [1](#Tab1){ref-type="table"}).Table 1*NPHS2* sequence variants identified in the Polish population of patients with steroid-resistant nephrotic syndrome (SRNS)Exon (intron)Nucleotide changeAmino acid changeEffectGenotypeGeographical distribution of the allelePositive family historyConsanguinityHomozygousCompound heterozygousCarrier A. Nonsense and frameshift mutations8c.948delTp.Ala317Leufs\*31Pathogenic010Central and Eastern Europe (Hungary, Poland, Germany)NoneNoneRuf et al. ([@CR15]); Kerti et al. ([@CR7])8c.1032delTp.Phe344Leufs\*5Pathogenic0110Poland (Kashubian region), Germany10/11 AR (five families)1Hinkes et al. ([@CR5]) B. Missense variants2c.322A\>Gp.Ile108ValBenign?001NovelNoneNone3c.413G\>Ap.Arg138GlnPathogenic401The most common in Europe (France, Germany, Italy, Switzerland, Spain, Hungary, Poland, Czech Republic)1/5 AR (one family)NoneWeber et al. ([@CR20]); Ruf et al. ([@CR15]); Caridi et al. ([@CR3]); Santín et al. ([@CR17]); Kerti et al. ([@CR7])5c.622G\>Ap.Ala208ThrPathogenic010The Netherlands, France, PolandNoneNoneLöwik et al. ([@CR9]); Weber et al. ([@CR20])5c.686G\>Ap.Arg229GlnRisk factor2148Polymorphism common in European populations15/24 AR (nine families)1Machuca et al. ([@CR11])5c.732T\>Cp.(=)Benign?001NovelNoneNone7c.868G\>Ap.Val290MetPathogenic011Central and Eastern Europe (Hungary, Poland, Germany), TurkeyNoneNoneKerti et al. ([@CR7])8c.890C\>Tp.Ala297ValPathogenic020Poland, Czech-American, North Africa2/2 AR (one family)NoneTsukaguchi et al. ([@CR18]); Machuca et al. ([@CR11]) C. Splice-site variants7/8c.873+1G\>Ap.?Pathogenic?100NovelNone1*AR* autosomal recessive inheritance

Ten sequence variants, including three novel ones, were identified in 34 (24 %) SRNS patients. Variants were located along the entire coding sequence of the gene. The most frequent *NPHS2* variant was the non-neutral polymorphism c.686G\>A (rs61747728, commonly referred to as p.R229Q), which was detected in 24 patients (21 %). In 14 of these, c.686G\>A contributed to disease-causing compound heterozygosity, whereas two patients were homozygous and eight patients were heterozygous for c.686G\>A without any further variants in *NPHS2*. All carriers of the c.1032delT mutation came from a confined geographical area, the Kashubian region in North Poland (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Geographical distribution of *NPHS2* sequence variants in the Polish population of steroid-resistant nephrotic syndrome (SRNS) patients. *Left* distribution of the *NPHS2* mutations in Poland. *Right* distribution of the *NPHS2* mutations in the Kashubian region of North Poland. *Gray shading* districts with the highest percentage of Kashubian inhabitants. The named dots represent major towns. Minor allele frequency (MAF) values for the non-neutral p.R229Q polymorphism are presented as %

Three novel *NPHS2* sequence variants were found. These included two exonic single nucleotide alterations, c.322A\>G and c.732T\>C, present in heterozygous state in individual patients and an intronic c.872+1G\>A substitution present in homozygous state in a child from a consanguineous marriage. None of the novel variants is catalogued in the three large human variation databases: dbSNP, 1000 Genomes and NHLBI Exome Variant Server. At the protein level, c.322A\>G results in the substitution of a non-conservative residue (p.I108V) by a similar hydrophobic branched amino acid within the hydrophobic intra-membrane domain, while c.732T\>C is a silent (synonymous) mutation. Accordingly, the SIFT and PolyPhen in silico algorithms advocate for their benign character. Nonetheless, the two exonic variants lie near splice-sites at the exon/intron boundaries and could affect mRNA processing. Likewise, the third novel variant affects the first nucleotide of the intron 8 and has been identified by in silico tools as a mandatory splice-site mutation.

Age of onset and the mutation detection rate {#Sec7}
--------------------------------------------

Mutations in the *NPHS2* gene were most frequent in patients diagnosed within the first year of life (26 %, 9/35), and in patients with congenital nephrotic syndrome in particular (33 %; 8/24). Toddlers and school children had the lowest rate of 8 % (7/84). Adolescents diagnosed with the disease aged over 10 years had an 18 % mutation detection rate (4/22). All teenagers were compound heterozygous cases for the c.686G\>A polymorphism and an *NPHS2* mutation.

Evaluation of the founder effect for *NPHS2* mutations in the Kashubian population {#Sec8}
----------------------------------------------------------------------------------

A total of 575 consecutive neonatal dry blood spots representative for five Kashubian districts of North Poland were evaluated for the p.R229Q polymorphism and the c.1032delT mutation in *NPHS2*. The genotype frequencies of the p.R229Q polymorphism were consistent with the Hardy--Weinberg equilibrium. The p.R229Q minor allele frequency (MAF) was 6.5 % for the entire group (Fig. [1](#Fig1){ref-type="fig"}). In the entire cohort, only one subject from the Koscierzyna district was found to carry a heterozygous c.1032delT mutation (frequency of the mutated allele \<1/1,000), without any other variants in the *NPHS2* gene.

Discussion {#Sec9}
==========

Currently, genetic screening in paediatric SRNS is based on initial testing of the entire coding sequence of *NPHS2*, with subsequent extended screening of other genes in line with the identified phenotype (age at onset, kidney biopsy findings, presence of extra-renal symptoms) (Santín et al. [@CR16]).

*NPHS2* gene mutations are estimated to account for 10--30 % of SRNS cases, depending on ethnicity, size of the analysed group, accuracy of the clinical diagnosis and the mean age at diagnosis (Santín et al. [@CR17]). The screening of the entire coding region of the *NPHS2* gene led to a conclusive diagnosis in 14 % of our unselected consecutive Polish SRNS cohort, a figure similar to the rates reported for other European populations (French: Weber et al. [@CR20]; German: Ruf et al. [@CR15]; Italian: Caridi et al. [@CR3]; Spanish: Santín et al. [@CR17]; Hungarian: Kerti et al. [@CR7]). Analysis of the mutation detection rate with respect to age at onset revealed the presence of two subgroups with relatively higher incidence of *NPHS2*-associated disease: infants and adolescents. Since mutations in the *NPHS2* gene lead to congenital structural defect of the podocytes, their association with the early onset of SRNS is already well acknowledged (Hinkes et al. [@CR5]). Then again, compound heterozygosity status for p.R229Q has been shown to be associated with later onset and more latent course of the disease (Machuca et al. [@CR11]; Lipska et al. [@CR8]). In our group, all teenagers diagnosed with podocin-associated SRNS were, indeed, found to be compound heterozygous for non-neutral p.R229Q, together with an *NPHS2* mutation.

The criteria for diagnosing podocin-associated SRNS include a homozygous *NPHS2* mutation, compound heterozygous *NPHS2* mutations or a heterozygous *NPHS2* mutation trans-associated with the non-neutral p.R229Q polymorphism (Machuca et al. [@CR11]). In line with these guidelines, in the subjects homozygous for the p.R229Q polymorphism, SRNS was not considered to be caused by this common podocin variant. Also, a single heterozygous *NPHS2* mutation was not sufficient for diagnosis, as it has been shown that the presence of a single *NPHS2* variant does not modify the risk of developing the disease (Caridi et al. [@CR3]).

We noted a geographical cluster of patients carrying the c.1032delT mutation in North Poland, for the most part in the Kashubian districts, suggestive of a founder effect (Fig. [1](#Fig1){ref-type="fig"}). Kashubs are an ethnic group of West Slavs who have populated Northern Poland since the Migration Period (5th to 7th century A.D.). Despite substantial co-inhabitation of the region by both Poles and Germans over the following centuries, this ethnic group has preserved their cultural identity (Obracht-Prondzynski and Wicherkiewicz [@CR12]). Such a divergence has also been observed on the genetic level. Confirmation of the genetic distinctiveness of the Kashubian from other Polish regional populations comes from studies of serum protein markers and Y-chromosomal SNPs and short tandem repeats (STRs), which have also shown hardly detectable German paternal ancestry admixture (Walter et al. [@CR19]; Rębała et al. [@CR14]). Further evidence comes from the recent mutational studies of a few Mendelian traits, where particular mutations have been almost exclusively detected in patients from this region. These include familiar hypercholesterolaemia (c.662A\>G mutation in the *LDLR* gene; Chmara et al. [@CR4]), familial breast cancer (c.3700_3704del in the *BRCA1* gene; Brozek et al. [@CR2]) and long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (c.1528G\>A mutation in the *HADHA* gene; Piekutowska-Abramczuk et al. [@CR13]). The latter study has demonstrated a seven times higher incidence rate of this disorder and proven a founder effect among Kashubian patients, which led to the introduction of a neonatal screening programme in the region.

Post-war resettlements resulted in homogenisation of the contemporary Polish paternal lineages (Rębała et al. [@CR14]). At present, the population of ca. 550,000 Kashubs is concentrated in five rural districts of the Pomeranian Region (Fig. [1](#Fig1){ref-type="fig"}), accounting for approximately 25 % of its contemporary residents. All but one of the c.1032delT mutation carriers live in this region. This mutation has not been catalogued in human variation databases to date, and the only patient in whom this mutation was hitherto described lives in Northern Germany (Hildebrandt, personal communication). However due to World War II-mediated massive human resettlements, one cannot exclude Kashubian origin of this patient.

To test our hypothesis of a Kashubian founder effect, we performed a population screening study in almost 600 consecutive neonates from North Poland. Only a single subject was found to be heterozygous for c.1032delT. The frequency of the non-neutral p.R229Q polymorphism, which was trans-associated with the mutation in all the Kashubian SRNS patients, was found to be two times higher than the average 3.5 % observed in most European populations (Machuca et al. [@CR11]). The regional particularities can be readily applied in the diagnostic setting. A cost-effective approach to genetic testing in patients from the Kashubian region would be to pre-screen exons 5 and 8 of *NPHS2* (loci of p.R229Q and c.1032delT, respectively).

Conversely, *NPHS2* mutational analysis in patients living in other provinces of Poland has to incorporate the entire coding sequence of the gene. Similarly to studies performed on other European populations, in the analysed group of patients, a few rare mutations located in diverse exons have been diagnosed (Weber et al. [@CR20]; Ruf et al. [@CR15]; Caridi et al. [@CR3]; Santín et al. [@CR17]; Kerti et al. [@CR7]). The most common mutation in Caucasian populations, namely, p.R138Q, was also the most common in Polish patients (with the exception of Kashubs). This was followed by two mutations typical for Central and Eastern European populations, namely, c.948delT and p.V290M. These variants have previously been reported not only in Slavic nations, but also in German and Hungarian patients (Ruf et al. [@CR15]; Kerti et al. [@CR7]), echoing the complex history of the region.

Conclusions {#Sec10}
===========

In an unselected national cohort of Polish steroid-resistant nephrotic syndrome (SRNS) patients, the most commonly detected mutation was c.1032delT, which was exclusively detected in patients from Kashubian districts of North Poland, suggestive of a founder effect. Most patients carried compound heterozygous mutations, together with the non-neutral p.R229Q polymorphism. We recommend first-line analysis of exons 5 and 8 (the respective loci of p.R229Q and c.1032delT) in patients from this region.
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